New Zealand markets closed

Insmed Incorporated (INSM)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
76.71-0.32 (-0.42%)
At close: 04:00PM EDT
75.71 -1.00 (-1.30%)
After hours: 05:02PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close77.03
Open77.00
Bid76.62 x 300
Ask76.95 x 300
Day's range75.57 - 77.93
52-week range20.16 - 77.93
Volume4,823,775
Avg. volume3,643,844
Market cap12.513B
Beta (5Y monthly)1.16
PE ratio (TTM)N/A
EPS (TTM)-5.23
Earnings date01 Aug 2024 - 05 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est81.67
  • PR Newswire

    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 18 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.

  • PR Newswire

    Additional Positive Data from Pivotal ASPEN Study of Brensocatib in Patients with Bronchiectasis to be Presented at the 7th World Bronchiectasis Conference

    Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that additional positive results from the ASPEN study, a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis, will be presented tomorrow, July 4, 2024, at the 7th World Bronchiectasis Conference (WBC) i

  • PR Newswire

    Insmed Announces Redemption of all $225 Million of Outstanding 1.75% Convertible Senior Notes Due 2025

    Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it has called all $225 million aggregate principal amount of its outstanding 1.75% Convertible Senior Notes Due 2025 (the "Notes") (CUSIP No. 457669AA7) for redemption on August 9, 2024 (the "Redemption Date"). Insmed is redeeming the Notes as permitted under Section 11.03 of the indenture governing the Notes (the "Indenture")